NEWS HIGHLIGHTSMedia Articles Related to Bystolic (Nebivolol)
New Consortium Paves The Way For Improved Treatment Of Hypertension And Associated Vascular Complications
Source: Hypertension News From Medical News Today [2009.11.18]
Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Kids with CKD Often Have Masked Hypertension (CME/CE)
Source: MedPage Today Nephrology [2009.11.13]
Many children with chronic kidney disease may have undetected hypertension, placing them at risk for enlarged hearts and future cardiovascular disease, a cross-sectional study showed.
Key Player Identified In Cascade That Leads To Hypertension-Related Kidney Damage
Source: Hypertension News From Medical News Today [2009.11.06]
A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel constrictor and inflammatory peptide, increases the number of T cells in the kidneys, which helps recruit other immune cells, causing inflammation and destruction.
A Recipe For Hypertension: High Fructose Corn Syrup
Source: Hypertension News From Medical News Today [2009.10.31]
A diet high in fructose increases the risk of developing high blood pressure (hypertension), according to a paper presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, California. The findings suggest that cutting back on processed foods and beverages that contain high fructose corn syrup (HFCS) may help prevent hypertension.
Hypertension Guidelines Reappraised In Light Of New Research
Source: Hypertension News From Medical News Today [2009.10.30]
A Task Force of the European Society of Hypertension have released the official European guidelines on the management and treatment of hypertension. The guidelines are an update of those published in 2007, and will be published in the November issue of the Journal of Hypertension.
Published Studies Related to Bystolic (Nebivolol)
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). [2009.06.09]
OBJECTIVES: In this pre-specified subanalysis of the SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) trial, which examined the effects of nebivolol in elderly heart failure (HF) patients, we explored the effects of left ventricular ejection fraction (EF) on outcomes, including the subgroups impaired EF (< or =35%) and preserved EF (>35%). BACKGROUND: Beta-blockers are established drugs in patients with HF and impaired EF, but their value in preserved EF is unclear... CONCLUSIONS: The effect of beta-blockade with nebivolol in elderly patients with HF in this study was similar in those with preserved and impaired EF.
The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. [2009.05]
BACKGROUND: Free radical-mediated oxidative stress has been implicated in the etiopathogenesis of several disorders. The aim of this study was to elucidate the effect of treatment with nebivolol on the metabolic state of oxidative stress, and antioxidant status markers in patients with cardiac syndrome-X (CSX), additionally, to compare with the effect of metoprolol treatment... CONCLUSION: We have shown that patients with CSX who taken nebivolol have lower serum MPO activity, levels of MDA and higher serum SOD activity, NOx levels when compared with metoprolol treatment. Exercise stress test parameters were also ameliorated in patients who had taken nebivolol in contrast to metoprolol. Nebivolol treatment may be a novel treatment strategy in cases with CSX in the future.
Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension. [2009.05]
Endothelial dysfunction, which is characterized by impairment of nitric oxide (NO) bioavailability, plays an important role in the development of arterial hypertension. The L-arginine-NO pathway is closely related to oxygen transport to tissue.
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. [2009.04]
BACKGROUND: The major clinical problem of Marfan syndrome (MFS) is the aortic root aneurysm, with risk of dissection when the root diameter approximates 5 cm. In MFS, a key molecule, transforming growth factor-beta (TGF-beta), normally bound to the extracellular matrix, is free and activated. In an experimental setting, TGF-beta blockade prevents the aortic root structural damage and dilatation. The angiotensin receptor 1 blockers (sartanics) exert an anti-TGF-beta effect; trials are now ongoing for evaluating the effect of losartan compared with atenolol in MFS. beta-Adrenergic blockers are the drugs most commonly used in MFS. The third-generation beta-adrenergic blocker nebivolol retains the beta-adrenergic blocker effects on heart rate and further exerts antistiffness effects, typically increased in MFS... CONCLUSION: The present study will add information about pharmacological therapy in MFS, supporting the new application of angiotensin receptor 1 blockers and finding beta-adrenergic blockers that may give more specific effects. Moreover, the study will further deepen understanding of the pathogenetic mechanisms that are active in Marfan syndrome through the pharmacogenomic and transcriptomic mechanisms that may explain MFS phenotype variability.
A comparison of atenolol and nebivolol in isolated systolic hypertension. [2008.02]
OBJECTIVES: Some beta-blockers are less effective in reducing central blood pressure than other antihypertensive drugs, which may explain the higher rate of events in subjects randomized to atenolol in recent trials. We hypothesized that nebivolol, a mixed beta-blocker/nitro-vasodilator, would be more effective than atenolol in reducing central blood pressure and augmentation index (AIx). The aim of the present study was to test this in a double-blind, randomized, cross-over study, in a cohort of subjects with isolated systolic hypertension... CONCLUSIONS: Nebivolol and atenolol have similar effects on brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia. Whether this will translate into differences in clinical outcome requires further investigation.
Clinical Trials Related to Bystolic (Nebivolol)
Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function [Recruiting]
Beta-blockers (BB) are an important treatment for high blood pressure and heart disease.
However beta-blockers can cause sexual dysfunction (SD) and this common side effect limits
successful use of this class of medications. Sexual side effects often result in drug
discontinuation, compromising therapy goals. The investigators are conducting the study to
determine if nebivolol, a newer beta blocker that is selective for receptors in the heart
and causes vasodilation in the body causes fewer sexual side effects, or even improves
sexual function, compared with metoprolol succinate.
Comparative Effects of Nebivolol Versus Placebo on Sodium Sensitivity of Blood Pressure in Hispanic Postmenopausal Women With Hypertension [Not yet recruiting]
2. 1 Research objectives:
The objective of this randomized, placebo-controlled, 2 period crossover clinical trial is
to determine the effects of nebivolol versus placebo on ambulatory blood pressure, the blood
pressure response to dietary sodium loading, and renal handling of an acute sodium load in
postmenopausal women with hypertension.
2. 1.1 Hypothesis:
Nebivolol will result in a blunted response of blood pressure to oral sodium administration
and improved handling of an intravenous sodium load in comparison with placebo in
hypertensive postmenopausal women.
2. 2 Research plan:
2. 2.1 Study design
The study will consist of a randomized crossover trial of the effects on salt sensitivity of
nebivolol. All study procedures will be carried out under the direct supervision of the
Principal Investigator in the outpatient and inpatient research unit of the University of
Miami Division of Clinical Pharmacology.
2. 2.2 Primary endpoints:
1. Change and percentage change in systolic, diastolic and mean blood pressure by ABPM
from final day of low sodium to the final day of high sodium in nebivolol versus
placebo
2. Differences in renal sodium excretion in response to an acute sodium load during
treatment with either nebivolol or placebo.
2. 2.3 Secondary endpoints
1. Change in clinic blood pressure following 4 weeks of outpatient nebivolol versus
placebo
2. Change in weight from final day of low sodium to the final day of high sodium in
nebivolol versus placebo
3. Change in 24-hour sodium and potassium excretion from last day of low sodium to last
day of high sodium
4. Asymmetrical dimethylarginine (ADMA)
A Study on the Long-Term Efficacy of Nebivolol After Withdrawal of Therapy [Recruiting]
This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with
stage 1 or stage 2 hypertension after the withdrawal of active medication.
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients [Recruiting]
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another
beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the
mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other
biomarkers.
Alternative in Beta Blocker Intolerance: The ABBI Trial [Recruiting]
In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in
cardiovascular patients who are not able to tolerate conventional beta blockers. A side
effect profile will be tracked and compared with previous beta blocker use.
The investigators hypothesize that Bystolic will be tolerated by many patients who are
intolerant of conventional blockers.
|
